Overview

A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201. The study will be divided into three parts: A, B, and C (NOT Performed)

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Regenera Pharma Ltd

Collaborators:

INC Research
Syneos Health